Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-03-24 DOI:10.1016/j.ejca.2025.115380

Rui Kitadai , Yusuke Okuma , Taro Shibata , Takashi Kohno , Takafumi Koyama

{"title":"Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository","authors":"Rui Kitadai , Yusuke Okuma , Taro Shibata , Takashi Kohno , Takafumi Koyama","doi":"10.1016/j.ejca.2025.115380","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Utilizing real-world data from Japan's C-CAT clinicogenomic repository, our study demonstrates a significant shift in cancer management through cancer genomic profiling (CGP) tests. The aim of this study is assessing the prevalence of cross-organ targeted genetic alterations and exploring the differences in treatment responses among cancer patients who underwent CGP tests.</div></div><div><h3>Methods</h3><div>Analyzing data from 60,256 patients in the C-CAT repository, we documented the prevalence of FDA-approved biomarkers, cross-organ genetic alterations, and treatment outcomes for tissue-agnostic therapies from June 2019 to December 2023.</div></div><div><h3>Results</h3><div>Biomarkers including <em>RET</em> rearrangement, <em>BRAF</em><sup><em>V600E</em></sup> mutation, and <em>NTRK</em> rearrangement showed varied therapeutic responses, underscoring the need for universal CGP testing to optimize patient outcomes. Notably, our findings highlight variations in response across different age groups, suggesting the potential for age-specific treatment strategies. Comparisons with the AACR Project GENIE database revealed broader implications for the global genomic landscape.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the crucial role of clinicogenomic repositories in advancing precision oncology across diverse populations, underscoring the utility of integrating clinical and genomic data in national repositories.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115380"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001613","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Utilizing real-world data from Japan's C-CAT clinicogenomic repository, our study demonstrates a significant shift in cancer management through cancer genomic profiling (CGP) tests. The aim of this study is assessing the prevalence of cross-organ targeted genetic alterations and exploring the differences in treatment responses among cancer patients who underwent CGP tests.

Methods

Analyzing data from 60,256 patients in the C-CAT repository, we documented the prevalence of FDA-approved biomarkers, cross-organ genetic alterations, and treatment outcomes for tissue-agnostic therapies from June 2019 to December 2023.

Results

Biomarkers including RET rearrangement, BRAF^V600E mutation, and NTRK rearrangement showed varied therapeutic responses, underscoring the need for universal CGP testing to optimize patient outcomes. Notably, our findings highlight variations in response across different age groups, suggesting the potential for age-specific treatment strategies. Comparisons with the AACR Project GENIE database revealed broader implications for the global genomic landscape.

Conclusion

This study emphasizes the crucial role of clinicogenomic repositories in advancing precision oncology across diverse populations, underscoring the utility of integrating clinical and genomic data in national repositories.

查看原文本刊更多论文

目的利用日本 C-CAT 临床基因组库的真实数据，我们的研究表明，通过癌症基因组图谱（CGP）检测，癌症治疗发生了重大转变。本研究的目的是评估跨器官靶向基因改变的发生率，并探索接受CGP检测的癌症患者在治疗反应上的差异。方法分析C-CAT储存库中60256名患者的数据，我们记录了2019年6月至2023年12月期间FDA批准的生物标志物、跨器官基因改变的发生率以及组织诊断疗法的治疗结果。结果包括RET重排、BRAFV600E突变和NTRK重排在内的生物标志物显示出不同的治疗反应，突出表明需要进行通用的CGP检测以优化患者预后。值得注意的是，我们的研究结果突显了不同年龄段患者的反应差异，这表明有可能制定针对不同年龄段的治疗策略。这项研究强调了临床基因组资料库在推动不同人群精准肿瘤学方面的关键作用，突出了在国家资料库中整合临床和基因组数据的实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.